What the Evidence Really Says About the Long-Term Health Risk of Untreated Mild Sleep Apnea
Mild sleep apnea health risks over ten and twenty years, weighed against what the trials and cohorts actually measured
You were told your apnea is mild and treatment is optional, so here is what the cohorts, the randomised trials and NICE guidance really say about leaving it alone for a decade.
The Short Answer on Mild Sleep Apnea Health Risks
The honest summary of mild sleep apnea health risks is narrower than most pages admit. The excess risk is real, it sits mainly in blood pressure rather than sudden cardiac events, and it is not shared equally by everyone carrying the label. Mild means an apnoea-hypopnoea index (AHI) of 5 to 14.9 events per hour, and what your AHI score actually measures matters more than the band it drops you into. Cohort data link mild apnoea to roughly doubled odds of high blood pressure. Randomised trials have not shown that treating it prevents heart attacks or strokes.
That gap between two kinds of evidence is the whole story. It explains why European practice defaults to watchful waiting. NICE guideline NG202, recommendation 1.5.1, tells UK clinicians to explain to people with mild OSAHS and no symptoms that treatment is not usually needed. Most consumer health pages imply the opposite.
Leaving mild apnoea alone is defensible, but only as an active choice, with things checked and a plan for what would change your mind. Passive neglect is what twenty years punishes.
- Mild sleep apnoea is an AHI of 5 to 14.9 events per hour.
- NICE NG202 says asymptomatic mild OSAHS usually needs no treatment.
What Mild Actually Means on a European Sleep Report
Mild obstructive sleep apnoea is a counting threshold, not a measure of strain on your body. Your report counts apnoeas and hypopnoeas per hour of sleep and assigns a band: mild 5 to under 15, moderate 15 to under 30, severe 30 or more. The NHS phrases mild as an AHI of 5 to 14.
How Europeans get tested
The European pathway starts at home. NICE NG202 offers home respiratory polygraphy first-line (1.3.1), home oximetry as a fallback (1.3.2), and in-laboratory polysomnography only after negative polygraphy with continuing symptoms (1.3.5). A home sleep apnoea test (HSAT) is the normal European starting point.
Why one night can give two severities
Hypopnoeas are scored differently depending on the rulebook. Two sets are in circulation, the AASM 2007 and AASM 2012 hypopnea scoring criteria, and they differ on the 3% versus 4% desaturation rule. The same recording can land in different severity bands depending on which one your laboratory applied. Ask which rule was used.
The mild band is crowded
In HypnoLaus (Heinzer, The Lancet Respiratory Medicine, 2015), 2121 home polysomnograms in Swiss adults aged 40 to 85 found a median AHI of 6.9 events per hour in women and 14.9 in men. The median middle-aged European woman is already inside the mild band. Moderate-to-severe sleep-disordered breathing affected 23.4% of women and 49.7% of men. The authors concluded the definition of the disorder should be revised.
Symptoms here are unglamorous: snoring, unrefreshing sleep, morning headache. Contributors include weight gain, nasal obstruction, alcohol at bedtime, back sleeping, ageing and menopause. The condition is OSAHS in the UK, SAHOS in France, Schlafapnoe in Germany, apnea obstructiva del sueño in Spain.
- Mild is a counting band, not a reading of how hard your body is working.
- Scoring rules alone can shift a borderline result across a severity threshold.
What Twenty Years of Cohort Data Show
Long-running cohorts do show harm signals at mild severity. In the Wisconsin Sleep Cohort, Peppard and colleagues (New England Journal of Medicine, 2000) found a baseline AHI of 5.0 to 14.9 carried an adjusted odds ratio of 2.03 (95% CI 1.29 to 3.17) for hypertension four years later, against an AHI of 0. The dose-response ran from 1.42 at AHI 0.1 to 4.9 up to 2.89 at AHI 15 or more.
Doubled odds sounds alarming until you convert it into events. Marin and colleagues (The Lancet, 2005) followed men in Zaragoza for a mean 10.1 years and published absolute rates. Nobody puts these in front of patients.
| Group (Marin, The Lancet, 2005) | Fatal CV events / 100 person-years | Non-fatal CV events / 100 person-years | Rough 10-year fatal projection per 100 men (our arithmetic) |
|---|---|---|---|
| Healthy controls | 0.30 | 0.45 | ~3 |
| Simple snorers | 0.34 | 0.58 | ~3.4 |
| Untreated mild-to-moderate OSA | 0.55 | 0.89 | ~5.5 |
| Untreated severe OSA | 1.06 | 2.13 | ~10.6 |
The mechanism most often proposed fits those associations. Nocturnal intermittent hypoxaemia and repeated arousals are linked to sympathetic activation and endothelial dysfunction, and in turn to non-dipping nocturnal blood pressure and, over years, to resistant hypertension, atrial fibrillation, incident stroke and transient ischaemic attack, and type 2 diabetes and insulin resistance. Association is the correct word throughout. For the cardiac side in depth, see how sleep apnoea and heart disease are connected.
Benjafield and colleagues (The Lancet Respiratory Medicine, 2019) estimated 936 million adults aged 30 to 69 with mild-to-severe OSA worldwide and 425 million with moderate-to-severe disease. Roughly 511 million therefore sit in the mild band, the group with the least evidence.
- Wisconsin (2000) links mild AHI to roughly doubled odds of hypertension in four years.
- Marin (2005) works out to a few extra fatal events per 100 untreated men per decade.
Where Standard Advice on Mild Sleep Apnea Health Risks Breaks Down
Two flaws run through nearly every page here. The first is quoting a relative risk with no absolute number and no time horizon, so a reader told their risk is doubled cannot tell whether that means 0.6% or 20% over a decade. The second is reading the randomised trials as proof that continuous positive airway pressure (CPAP) protects the heart, or as proof that mild apnoea is harmless. Neither reading survives the trial designs.
| Trial | Population | CPAP adherence | Follow-up | Result |
|---|---|---|---|---|
| MERGE (Wimms, Lancet Respiratory Medicine, 2020) | 233 patients, 11 UK centres, AHI 5 to under 15 | Not reported here | 3 months | SF-36 vitality up 10.0 points (95% CI 7.2 to 12.8). Endpoint was quality of life, not events. |
| MOSAIC (Craig, Thorax, 2012) | 391 patients, UK and Canada, ODI above 7.5/h, minimally symptomatic | Median 2h39m per night; 22% stopped | Not reported here | Epworth score improved by 2.0 points; calculated 5-year vascular risk did not. |
| SAVE (McEvoy, New England Journal of Medicine, 2016) | 2717 adults, moderate-to-severe OSA with existing cardiovascular disease | Mean 3.3 hours per night | Mean 3.7 years | Events 17.0% versus 15.4%, hazard ratio 1.10 (95% CI 0.91 to 1.32). Snoring and sleepiness improved. |
Why the null trials cannot clear mild apnoea
Four design realities explain the contradiction. CPAP adherence hours per night were low, a median 2 hours 39 minutes in MOSAIC and a mean 3.3 hours in SAVE, so much of each night went untreated. Follow-up ran 3.7 years at longest, against a condition the cohorts track over twenty. Sleepy patients were excluded from randomisation to no treatment on ethical grounds, which removes the phenotype most likely to benefit. And people who stay on treatment tend to be healthier in ways adjustment cannot fully strip out.
Neither trial was built for the mild, sleepy patient. MOSAIC recruited people with too few symptoms to warrant CPAP. SAVE recruited moderate-to-severe disease in people who already had cardiovascular disease.
Europe's own evidence body calls it open
NICE published NG202 on 20 August 2021 with an unresolved research recommendation attached, asking what the clinical and cost effectiveness of auto- and fixed-level CPAP for mild OSAHS actually is. The European Sleep Apnoea Database (ESADA) shows the same skew: a 2026 analysis drew on 10,916 participants, 76.2% of them moderate-to-severe. Mild apnoea is under-studied partly because it is under-recruited.
- MERGE is the only randomised trial designed for mild OSA, and it measured vitality.
- No trial evidence of benefit is not the same as evidence that mild apnoea is harmless.
Three Things That Tell You More Than Your AHI Alone
Your AHI is an event counter. It does not record how deeply you desaturate, how long each dip lasts, or how you feel at three in the afternoon. Three things carry more weight, and all sit in reports you may already have.
1Hypoxic burden, not event count
Azarbarzin and colleagues (European Heart Journal, published on behalf of the European Society of Cardiology, 2019) concluded that unlike the AHI, the hypoxic burden strongly predicted cardiovascular mortality. The highest quintile carried a hazard ratio of 1.96 (95% CI 1.11 to 3.43) in the Sleep Heart Health Study. Find your oxygen desaturation index (ODI) and your lowest recorded saturation. A mild AHI with deep, long dips is a different animal from a mild AHI with shallow ones.
2Which symptom phenotype you are
Mazzotti and colleagues (American Journal of Respiratory and Critical Care Medicine, 2019) identified four subtypes in the Sleep Heart Health Study: disturbed sleep 12.2%, minimally symptomatic 32.6%, excessively sleepy 16.7%, moderately sleepy 38.5%. At comparable AHI, the excessively sleepy subtype showed hazard ratios of 1.7 to 2.4 for incident cardiovascular disease. A 2025 follow-up in ERJ Open Research found that subtype had higher incident major adverse cardiovascular events (MACE), hazard ratio 1.62, independently of hypoxic burden. Score yourself on the Epworth Sleepiness Scale and the STOP-Bang questionnaire, and be honest about excessive daytime sleepiness (EDS).
3Whether the number is drifting
Mild apnoea can worsen. Upper airway collapsibility (Pcrit) shifts with weight, muscle tone, nasal patency and hormonal change, and endotypes such as arousal threshold and loop gain differ from person to person. One AHI is a snapshot of one night. Two readings five years apart are a trajectory, and a trajectory is what a twenty-year decision needs. Some people also have positional obstructive sleep apnoea, where events cluster on the back.
- Hypoxic burden predicted cardiovascular mortality where the AHI did not (Azarbarzin, 2019).
- Two people with an AHI of 10 can face very different ten-year outlooks.
Driving, Licences and the EU Rules Nobody Explains
Mild sleep apnoea sits below the EU driving-licence threshold. Directive 2014/85/EU, amending Annex III of the Driving Licence Directive, defines moderate obstructive sleep apnoea syndrome as an AHI of 15 to 29 and severe as 30 or more, both associated with excessive daytime sleepiness. An AHI of 5 to 14.9 falls outside it entirely.
For treated drivers who show adequate control, the same Directive sets periodic medical review at intervals not exceeding three years for Group 1 car licences and one year for Group 2 professional licences.
The concern is not theoretical. Tregear and colleagues (Journal of Clinical Sleep Medicine, 2009) found in a meta-analysis that the mean crash-rate ratio linked to obstructive sleep apnoea likely falls between 1.21 and 4.89.
- Directive 2014/85/EU sets its threshold at AHI 15 with sleepiness, so mild sits below it.
- DVLA excessive sleepiness notification is triggered by symptoms, not by your AHI band.
A Ten-Year Monitoring Plan If You Choose Not to Treat
Surveillance instead of treatment is reasonable for minimally symptomatic obstructive sleep apnoea in the mild band. It is only reasonable if the surveillance happens. Here is the protocol. It costs nothing.
- Re-score sleepiness twice a year. Use the Epworth Sleepiness Scale. A rising score is the clearest single sign your phenotype has changed.
- Check blood pressure at home quarterly. Mention early-morning elevation to your doctor, since non-dipping overnight pressure is the mechanism most consistently linked to this condition.
- Track weight and neck circumference yearly. Weight gain is one of the clearest reasons to book a repeat test, and the factor you can most readily change.
- Ask a bed partner once a year. Louder snoring, new witnessed pauses or gasping arousals are data you cannot collect on yourself.
- Re-test if a trigger fires. New or resistant hypertension, new atrial fibrillation, menopause, more alcohol, or significant weight gain each justify a repeat home sleep apnoea test rather than repeat reassurance.
One caveat when you re-test. Because scoring rules differ, ask the laboratory to apply the same criteria as your first study, or at least to state which rule it used. Otherwise you compare an AASM 2012-scored night with a 2007-scored night and read a change that is administrative, not biological.
- Surveillance is a real clinical strategy, but only with defined triggers.
- Match scoring criteria between studies or the comparison means little.
If You Decide Not to Do Nothing
European practice already has a ladder for symptomatic mild OSAHS. NICE NG202 recommendation 1.5.2 offers fixed-level CPAP on the NHS where symptoms affect quality of life and usual daytime activities, immediately if priority factors apply, such as a vocational driving job or unstable cardiovascular disease. Recommendation 1.5.7 offers a customised or semi-customised mandibular advancement splint where an adult with optimal dental and periodontal health cannot tolerate or declines CPAP.
The counterweight is adherence. Among 222 first-time CPAP users diagnosed with mild sleep apnoea by home testing, only 57, or 25.7%, were adherent long term (BMC Pulmonary Medicine, 2023). Prescribing a machine that roughly three-quarters of that cohort stopped using is not risk reduction on its own.
That is why the European ladder includes lower-burden mechanical options. Weight loss, less alcohol before bed, treating nasal obstruction and positional measures come first. A mandibular splint sits next. An intranasal stent occupies a similar slot: Back2Sleep is a CE-certified Class I soft silicone intranasal stent under the EU Medical Device Regulation, for snoring and mild-to-moderate obstructive sleep apnoea, needing no prescription, no electricity and no tubing, with four sizes in the starter kit. For a side-by-side view, see how the mild-to-moderate options compare on burden and evidence.
- NICE NG202 offers CPAP first for symptomatic mild OSAHS, and a mandibular advancement splint if CPAP is declined.
- Lower-burden options exist because adherence is the constraint, not because they prevent events.
What Back2Sleep Users Say
Frequently Asked Questions
Is mild sleep apnea dangerous if left untreated?
Mild sleep apnea carries a measurable but modest excess risk. The Wisconsin Sleep Cohort (2000) linked an AHI of 5 to 14.9 with roughly doubled odds of hypertension within four years. Marin's Lancet cohort (2005) recorded 0.55 fatal cardiovascular events per 100 person-years untreated, against 0.30 in healthy men. Your symptoms and oxygen dips matter more than the label.
Do I need a CPAP machine for mild sleep apnea?
Not automatically. NICE guideline NG202 says people with mild OSAHS and no troubling symptoms usually need no treatment. CPAP is offered on the NHS when symptoms affect quality of life, or immediately for priority groups such as vocational drivers. A mandibular advancement splint is offered when CPAP is declined or not tolerated.
Does mild sleep apnea shorten your life expectancy?
No study cited here shows shortened life expectancy from mild sleep apnea alone. Marin's 2005 Lancet cohort found only untreated severe disease reached statistical significance for fatal cardiovascular events. Untreated mild-to-moderate disease ran at 0.55 fatal events per 100 person-years across a mean 10.1 years, a small absolute difference.
Do I have to tell the DVLA about mild sleep apnoea?
The DVLA trigger is symptoms, not your AHI number. The NHS states that if sleep apnoea with excessive sleepiness is confirmed, you must not drive until symptoms are controlled. EU Directive 2014/85/EU starts its licensing thresholds at AHI 15 with sleepiness, so mild apnoea sits below the numeric threshold.
How often should mild sleep apnea be re-tested?
Re-test on triggers rather than a fixed calendar. New or resistant hypertension, new atrial fibrillation, menopause, significant weight gain, increased alcohol, or a rising Epworth Sleepiness Scale score each justify a repeat home sleep apnoea test. Ask the laboratory to use the same scoring criteria as your first study.
Can a home sleep apnea test show whether mild apnea is getting worse?
Yes, within limits. NICE NG202 makes home respiratory polygraphy the first-line European test, and repeating it shows whether your AHI is drifting upward. Ask for your oxygen desaturation index as well, since hypoxic burden predicted cardiovascular mortality better than event count in a 2019 European Heart Journal analysis.
Can mild sleep apnea get worse over time?
Yes. Upper airway collapsibility changes with weight gain, ageing, menopause, alcohol and nasal obstruction, so an AHI of 8 today can cross into the moderate band later. One night's reading is a snapshot. Two readings several years apart give you the trajectory a long-term decision actually needs.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.